Zane Gray

Zane Gray

Auto-generated profile, based on publicly available information

Zane Gray

Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2025 in Cancer Discovery
Verified
Journal Article
Closed access
AMArijit Mal
Arijit Mal
BXBingqing Xie
Bingqing Xie
ZGZane Gray
Zane Gray
CSCharlotte Small
Charlotte Small
SRSusmita G. Ramanand
Susmita G. Ramanand
JBJames Brugarolas
James Brugarolas
Patients with renal cell carcinoma (RCC) and hypercalcemia (HC) have worse outcomes. HC often involves parathyroid hormone–related protein (PTHrP), and the role of hypoxia-inducible factor 2 (HIF-2) is incompletely understood. Leveraging RCC tumorgraft (TG) models of HC, which were characterized by tumor cell–autonomous inflammatory/immune signatures, we show that HIF-2 inhibition with PT2399 frequently normalized calcium, downregulated circulating PTHrP, and reduced HIF-2 binding to the PTHLH (PTHrP) promoter. Likely contributing to the selective induction of PTHrP in a subset of HIF-2–dependent tumors, the PTHLH locus was generally more accessible in TG(HC). However, PTHLH chromatin accessibility was grossly unaffected by PT2399, unlike elsewhere (including the EPO locus in a TG with paraneoplastic polycythemia). As in TGs, paraneoplastic HC in patients was associated with clear-cell (cc)RCC (and sarcomatoid/rhabdoid differentiation) and was rapidly corrected by PT2977/belzutifan, which unlike bisphosphonates downregulated PTHrP. Our data support evaluating HIF-2 antagonists for ccRCC patients with paraneoplastic HC, which may serve as a predictive biomarker. Significance: This study uncovers a direct role for HIF-2 in driving humoral HC of malignancy in ccRCC through transcriptional activation of PTHLH (encoding PTHrP), identifies HC (and PTHrP) as potentially predictive biomarkers of HIF-2 engagement, and sets a foundation for the evaluation of HIF-2 antagonists for HC management in patients.

1 December 2025 in JU Open Plus
Verified
Journal Article
Open access
SASarah Attia
Sarah Attia
ZGZane N. Gray
Zane N. Gray
QCQi Cai
Qi Cai
SKSanjeeva P. Kalva
Sanjeeva P. Kalva
MCMoaz M. Choudhary
Moaz M. Choudhary
JWJue Wang
Jue Wang
Renal cell carcinoma (RCC) rarely metastasizes to the vagina, with approximately 80 cases reported, and no established treatment guidelines exist for management. We report a case of a 57-year-old woman with heavily pretreated, metastatic clear cell RCC who developed a symptomatic vaginal metastasis refractory to multiple systemic therapies and palliative radiation. She achieved complete clinical remission and significant radiographic regression following a novel combination of belzutifan (hypoxia-inducible factor 2 alpha inhibitor) and transarterial embolization, both well tolerated. This is the first documented case of this combined approach for RCC vaginal metastasis, suggesting a promising therapeutic strategy for managing rare, refractory metastatic sites.


18 June 2026
Verified
Other
Open access
AMArijit Mal
Arijit Mal
BXBingqing Xie
Bingqing Xie
ZGZane Gray
Zane Gray
CSCharlotte Small
Charlotte Small
SRSusmita G. Ramanand
Susmita G. Ramanand
JBJames Brugarolas
James Brugarolas
Gene set enrichment analysis of converging HIF-2 dependent genes

18 June 2026
Verified
Other
Open access
AMArijit Mal
Arijit Mal
BXBingqing Xie
Bingqing Xie
ZGZane Gray
Zane Gray
CSCharlotte Small
Charlotte Small
SRSusmita G. Ramanand
Susmita G. Ramanand
JBJames Brugarolas
James Brugarolas
PT2399 is ineffective against lung squamous cell carcinoma TG line with paraneoplastic hypercalcemia

18 June 2026
Verified
Other
Open access
AMArijit Mal
Arijit Mal
BXBingqing Xie
Bingqing Xie
ZGZane Gray
Zane Gray
CSCharlotte Small
Charlotte Small
SRSusmita G. Ramanand
Susmita G. Ramanand
JBJames Brugarolas
James Brugarolas
Tumor volume after PT2399 treatment for 4 days